Contact us about stem cell services
Press Ctrl (Windows) or Cmd (Apple) to choose multiple answers
Go CMO: guidelines for choosing a stem cell therapy manufacturing partner
As the stem cell therapy industry continues to grow, so does the need for trusted contract manufacturing organization (CMO) partners that can provide a safe, reliable source of cells for therapeutic development. A CMO is a company that provides manufacturing services to other companies on a contract basis. In cell therapy manufacturing, such partners are important because they have crucial technical, regulatory, and manufacturing expertise.
Choose a CMO based on these key selection criteria:
- Expert sourcing of starting material. Your CMO should work with you to define the exact specifications of your cells and retrieve them from FDA-compliant sources according to FDA guidelines.
- Established protocols. To ensure product safety in downstream clinical cell therapy applications, your CMO should have a feeder-free and animal/human-component-free method for generating robust cell lines.
- GMP compliance. Make sure you pick a CMO that operates according to guidelines for Good Manufacturing Practices, so you can be confident that the products are high quality and meet regulatory standards.
- Extensive experience and strong reputation for partnerships. You'll want to make sure that your CMO has a history of successful partnerships, so you know you can depend on them.
- Customized solutions. The best CMOs will have experience providing custom solutions to their partners and will be able to support them with innovative solutions across all stages of the development process.
Takara Bio was recently recognized by the stem cell industry blog BioInformant as the first company in the world to offer CMO services for the derivation and banking of human embryonic stem cells (hESCs) under GMP conditions. Read the full article to learn more about what makes Takara Bio the ideal partner for generating hESCs as starting material for downstream clinical cell therapy applications.
- Accurate detection of SNVs and CNVs from 5-cell inputs in a single, low-pass sequencing run
- Using the power of RNA-seq to characterize brain cell types
- When your his-tagged constructs don't bind
- Taking the SMARTer approach to RNA-seq of FFPE tissues
- Maximizing transduction efficiency in hematopoietic cells
- Efficient nonviral T-cell engineering: CRISPR takes a giant step towards the clinic
- Amplifying our understanding of breast cancer metastases
- Top 5 considerations when automating single-cell sequencing
- What's inside automated single-cell RNA-seq platforms?
- Women in science at TBUSA
- Career spotlight: product manager
- Career spotlight: technical writer
- Career spotlight: field applications scientist
- Career spotlight: technical support scientist
- Career spotlight: associate director of R&D
- 5 tips to make your single-cell RNA-seq experiments a success
- Cancer immunotherapy
- Customer spotlight: profiling transcription factors with CUT&RUN sequencing
- Web and mobile apps
- Successful knockout experiments
- Using UMTs in NGS experiments
- One-step vs. two-step RT-qPCR
- Avoiding DNA contamination in PCR
- Choosing a CMO partner for stem cell therapy manufacturing
- 20 years of human stem cell research
- Better biobanking with high-throughput qPCR
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.